Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification

Baratta, Francesco; D’Erasmo, Laura; Bini, Simone; Pastori, Daniele; Angelico, Francesco; Ben, Maria Del; Arca, Marcello; Costanzo, Alessia Di

doi:10.1016/j.atherosclerosis.2022.08.011

Cited by 17 publications

(17 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of diastolic dysfunction was significantly increased in association with HBV cirrhosis. Yuan et al agreed with our findings, as they reported that impaired relaxation was more noticed in patients with chronic HBV infection compared to patients with compensated liver disease [3]. The previous difference in E/A ratio detected in HBV subgroups was not observed in subgroups of HCV and NASH groups.…”

Section: Discussionsupporting

confidence: 93%

“…Similarly, uncontrolled heart disease could also lead to hepatic damage [1,2]. The presence of synchronous cardiac and hepatic diseases is a documented predictor of mortality, as it was previously reported that about 25% of cirrhotic patients died of poor cardiac function [3]. The hepatitis C virus (HCV) is the main cause of liver disease in Egypt [4].…”

Section: Introductionmentioning

confidence: 99%

“…The hepatitis B virus (HBV) is also an important viral pathogen causing liver cirrhosis. HBV patients with either compensated or decompensated hepatic disease could present with multiple manifestations, including cardiac disease [3,7]. Non-alcoholic steatohepatitis (NASH) represents a special type of chronic liver disease that is linked to metabolic syndrome and insulin resistance [8,9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative evaluation of cardiac health in patients with chronic liver disease secondary to HCV, HBV, and NASH

Omar

Zaghla

Omara

et al. 2022

ijhs

View full text Add to dashboard Cite

Background: There is a documented relationship between chronic liver disease and cardiac dysfunction. The current investigation aims to compare the cardiac health in patients with chronic liver disease secondary to HCV, HBV, and NASH. Patients and Methods: This prospective study included 150 patients divided into three groups; Group I (50 HCV cases), Group II (50 HBV cases), and Group III (50 NASH cases). Each group was subdivided into two equal subgroups; the A subgroup included patients without liver cirrhosis, and the B subgroup included patients with liver cirrhosis. The assessment included laboratory biomarkers, transabdominal ultrasound, fibroscan, echocardiography, and carotid doppler. Results: EF had mean values of 62.58, 62.8, and 64.14%, whereas prolonged QT interval was noted in 30%, 40%, and 37% of patients in the three groups, respectively. E/A ratios > 1 were detected in 70%, 66%, and 72% of patients, while carotid atherosclerosis was detected in 28%, 28%, and 32% in the same three groups, respectively. All of the previous parameters were comparable between the three main groups. On comparing subgroups A to B, prolonged QT intervals, carotid atherosclerosis, and decreased EF were more noticed in the latter.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative evaluation of cardiac health in patients with chronic liver disease secondary to HCV, HBV, and NASH

Omar

Zaghla

Omara

et al. 2022

ijhs

View full text Add to dashboard Cite

show abstract

“…In addition, some common polymorphisms of genes involved in lipid metabolism seem to be associated with the development of liver steatosis and HCC. Several meta-analyses [ 56 , 57 , 58 , 59 ] investigated the risk of HCC development in ft homozygous carriers of the PNPLA3 I148M variant, and the identified relative risk ranged from 1.67 to 2.68.…”

Section: Discussionmentioning

confidence: 99%

Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study

Brozzetti

D’Alterio

Bini

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) usually develops in cirrhotic liver, with high recurrence rates. However, considering its increasing detection in non-cirrhotic liver, the choice of treatment assumes particular relevance. This study aimed to investigate outcomes of patients among BCLC stages and enrolled for surgical resection (SR) according to a more complex evaluation, to establish its safety and efficacy. A total of 186 selected HCC patients (median age 73.2 yrs), submitted to SR between January 2005 and January 2021, were retrospectively analyzed. Of which, 166 were staged 0, A, B according to the BCLC system, while 20 with a single large tumor (>5 cm) were classified as stage AB. No perioperative mortality was recorded; complications occurred in 48 (25.80%) patients, and all but two were Clavien–Dindo grade I–II. Median follow-up was 9.2 years. Subsequently, 162 recurrent patients (87,1%) were selected for new treatments. Comparable overall survival rates (OS) were observed at 1, 3, 5, and 10 years in 0, A, B and AB stages (p = 0.2). Eventually, the BCLC-B group was matched to 40 BCLC-B patients treated (2015-2021) with TACE. Significant differences in baseline characteristics (p <0.0001) and in OS were observed at 1 and 3 years (p <0.0001); a significant difference was also observed in oncological outcomes, in terms of the absence, residual, or relapse of disease (p <0.05). Surgery might be a valid treatment in HCC for patients affected by chronic liver disease in a condition of compensation, up to BCLC-B stage. Surgical indication for liver resection in case of HCC should be extensively revised.

show abstract

“…Metabolic syndrome, NAFLD, and imaging biomarkers predicted long-term risk of cardiac events [ 9 ]. Subjects with genetic NAFLD and without metabolic disturbances do not have increased cardiovascular risk, whereas those with metabolic disease such as diabetes, have high cardiometabolic risks [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study

Chung

Jeong

Cho

et al. 2022

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) commonly coexist. However, NAFLD’s effect on mortality in Asian patients with type 2 diabetes awaits full elucidation. Therefore, we examined NAFLD-related all-cause and cause-specific mortality in a nationwide Asian population with type 2 diabetes. Methods We included patients who had undergone general health checkups between 2009 and 2012 using the National Health Insurance Service database linked to death-certificate data. Hepatic steatosis was defined as a fatty liver index (FLI) ≥ 60, and advanced hepatic fibrosis was determined using the BARD score. Findings During the follow-up period of 8.1 years, 222,242 deaths occurred, with a mortality rate of 14.3/1000 person-years. An FLI ≥ 60 was significantly associated with increased risks of all-cause and cause-specific mortality including cardiovascular disease (CVD)-, cancer-, and liver disease (FLI ≥ 60: hazard ratio [HR] = 1.02, 95% confidence interval [CI] 1.01–1.03 for all-cause; 1.07, 1.04–1.10 for CVD; 1.12, 1.09–1.14 for cancer; and 2.63, 2.50–2.77 for liver disease). Those with an FLI ≥ 60 and fibrosis (BARD ≥ 2) exhibited increased risks of all-cause (HR, 95% CI 1.11, 1.10–1.12), CVD- (HR, 95% CI 1.11, 1.09–1.14), cancer- (HR, 95% CI 1.17, 1.15–1.19), and liver disease-related (HR, 95% CI 2.38, 2.29–2.49) mortality. Conclusion Hepatic steatosis and advanced fibrosis were significantly associated with risks of overall and cause-specific mortality in patients with type 2 diabetes. Our results provide evidence that determining the presence of hepatic steatosis and/or fibrosis potentially plays a role in risk stratification of mortality outcomes in patients with type 2 diabetes mellitus.

show abstract

Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification

Cited by 17 publications

References 142 publications

Comparative evaluation of cardiac health in patients with chronic liver disease secondary to HCV, HBV, and NASH

Comparative evaluation of cardiac health in patients with chronic liver disease secondary to HCV, HBV, and NASH

Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study

The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study

Contact Info

Product

Resources

About